The sale is small and part of a pre-arranged 10b5-1 plan, so it carries minimal signaling value. Monitor for any acceleration of insider selling or changes in the 10b5-1 plan, which could indicate a shift in insider sentiment.
Price Chart
Executive Summary
Director Leonard Post filed a Form 144 to sell 3,000 shares of CG Oncology common stock, with an estimated aggregate market value of $185,520. The sale is planned for October 15, 2026, and is tied to the exercise of stock options, with proceeds to be used for cash. This is a relatively small sale relative to the company's market cap and appears to be part of a pre-arranged 10b5-1 trading plan, as indicated by prior sales in August and September 2026.
Key Facts
- Director Leonard Post intends to sell 3,000 shares of CG Oncology common stock.
- Estimated aggregate market value of the proposed sale is $185,520.
- The sale is scheduled for October 15, 2026, and is tied to the exercise of stock options.
- Post has prior 10b5-1 plan sales in August and September 2026, suggesting this is a routine, pre-planned transaction.
- The filing indicates the sale is for cash and not part of a hedging or derivative strategy.
Financial Impact
Proposed sale of 3,000 shares valued at approximately $185,520, which is a small fraction of the company's market cap and the insider's likely holdings.
Risk Factors
- Insider selling, even if pre-planned, can be perceived negatively by the market if volume increases.
- The stock option exercise could lead to modest dilution if not offset by buybacks.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010274 |
| Document: 0001950047-26-010274-index.html | 0001950047-26-010274 |
| Document: 0001950047-26-010274.txt | 0001950047-26-010274 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 9d ago | 3 | $61.93 | awaiting T+20 | awaiting T+20 | $63.96 (+3.28%) |
Oct 15, 2026 13d ago | 144 | $59.85 | awaiting T+20 | awaiting T+20 | $63.96 (+6.87%) |
Oct 12, 2026 16d ago | Institutional Cluster | $63.13 | awaiting T+20 | awaiting T+20 | $63.96 (+1.31%) |
Aug 6, 2026 11w ago | Press Release | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $63.96 (+14.55%) |
Aug 6, 2026 11w ago | 424B5 | $74.85 $74.33 | ▲ +0.69% | ▲ +1.29% | $63.96 (+14.55%) |
Jul 27, 2026 13w ago | Press Release | $72.62 $78.95 | ▲ +8.72% | ▲ +5.34% | $63.96 (−11.93%) |
Jul 17, 2026 14w ago | Insider Cluster | $70.19 $77.11 | ▲ +9.86% | ▲ +5.74% | $63.96 (−8.88%) |
Jul 16, 2026 15w ago | Court Ruling | $71.85 $75.03 | ▲ +4.43% | ▼ −0.02% | $63.96 (−10.98%) |
Jun 24, 2026 18w ago | 144 | $72.84 $71.12 | ▼ −2.36% | ▼ −2.89% | $63.96 (−12.19%) |
Jun 22, 2026 18w ago | 144 | $65.73 $70.19 | ▲ +6.79% | ▲ +5.63% | $63.96 (−2.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers